Terms: = Pancreatic cancer AND SDHA, SDH2, 6389, ENSG00000073578, FP, P31040, SDHF AND Treatment
24 results:
1. Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis.
Jiang Z; Wu F; Laise P; Takayuki T; Na F; Kim W; Kobayashi H; Chang W; Takahashi R; Valenti G; Sunagawa M; White RA; Macchini M; Renz BW; Middelhoff M; Hayakawa Y; Dubeykovskaya ZA; Tan X; Chu TH; Nagar K; Tailor Y; Belin BR; Anand A; Asfaha S; Finlayson MO; Iuga AC; Califano A; Wang TC
Cell Stem Cell; 2023 Aug; 30(8):1091-1109.e7. PubMed ID: 37541213
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
3. Survey of US Medical Oncologists' Practices and Beliefs Regarding
Koo K; Pasternak AL; Henry NL; Sahai V; Hertz DL
JCO Oncol Pract; 2022 Jun; 18(6):e958-e965. PubMed ID: 35239419
[TBL] [Abstract] [Full Text] [Related]
4. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.
Chen H; Bian A; Yang LF; Yin X; Wang J; Ti C; Miao Y; Peng S; Xu S; Liu M; Qiu WW; Yi Z
Oncogene; 2021 Feb; 40(8):1440-1457. PubMed ID: 33420372
[TBL] [Abstract] [Full Text] [Related]
5. Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Gmeiner WH; Dominijanni A; Haber AO; Ghiraldeli LP; Caudell DL; D'Agostino R; Pasche BC; Smith TL; Deng Z; Kiren S; Mani C; Palle K; Brody JR
Mol Cancer Ther; 2021 Mar; 20(3):553-563. PubMed ID: 33361273
[TBL] [Abstract] [Full Text] [Related]
6. Impact of prior interventional treatment on the complications after Frey procedure for chronic pancreatitis.
Merdrignac A; Bergeat D; Robin F; Gaignard E; Turner K; Rayar M; Meunier B; Boudjema K; Sulpice L
Langenbecks Arch Surg; 2019 Nov; 404(7):825-830. PubMed ID: 31654115
[TBL] [Abstract] [Full Text] [Related]
7. Chemotherapy response of pancreatic cancer by diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) in an orthotopic mouse model.
Wu L; Li J; Fu C; Kühn B; Wang X
MAGMA; 2019 Aug; 32(4):501-509. PubMed ID: 30825012
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Khan K; Rane JK; Cunningham D; Rao S; Watkins D; Starling N; Kalaitzaki E; Forster M; Braconi C; Valeri N; Gerlinger M; Chau I
Clin Colorectal Cancer; 2019 Mar; 18(1):64-71.e1. PubMed ID: 30404764
[TBL] [Abstract] [Full Text] [Related]
9. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract] [Full Text] [Related]
10. 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation.
Kumar D; Singh G; Sharma P; Qayum A; Mahajan G; Mintoo MJ; Singh SK; Mondhe DM; Bedi PMS; Jain SK; Gupta GK
Anticancer Agents Med Chem; 2018; 18(1):57-73. PubMed ID: 28925877
[TBL] [Abstract] [Full Text] [Related]
11. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
[TBL] [Abstract] [Full Text] [Related]
12. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy.
Granata V; Fusco R; Setola SV; Piccirillo M; Leongito M; Palaia R; Granata F; Lastoria S; Izzo F; Petrillo A
World J Gastroenterol; 2017 Jul; 23(26):4767-4778. PubMed ID: 28765698
[TBL] [Abstract] [Full Text] [Related]
13. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
[TBL] [Abstract] [Full Text] [Related]
14. Therapeutic concentrations of valproate but not amitriptyline increase neuropeptide Y (NPY) expression in the human SH-SY5Y neuroblastoma cell line.
Farrelly LA; Savage NT; O'Callaghan C; Toulouse A; Yilmazer-Hanke DM
Regul Pept; 2013 Sep; 186():123-30. PubMed ID: 23994577
[TBL] [Abstract] [Full Text] [Related]
15. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
Han X; Ji Y; Zhao J; Xu X; Lou W
Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
[TBL] [Abstract] [Full Text] [Related]
16. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.
Palwai NR; Zang XP; Harrison RG; Benbrook D; Pento JT
Pharmacology; 2009; 84(5):271-5. PubMed ID: 19797936
[TBL] [Abstract] [Full Text] [Related]
17. Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
Shibagaki K; Fujita K; Nakayama S; Takenaka M; Fukuba N; Matsui S; Ozaka M; Yoshinaga H; Masuzawa A; Watanabe A; Fujiwara H; Sugawara A; Fujita T; Mukai H; Kinoshita Y
Int J Clin Oncol; 2008 Feb; 13(1):74-7. PubMed ID: 18307024
[TBL] [Abstract] [Full Text] [Related]
18. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
Yonemori K; Okusaka T; Ueno H; Morizane C; Takesako Y; Ikeda M
Hepatogastroenterology; 2007 Dec; 54(80):2383-6. PubMed ID: 18265670
[TBL] [Abstract] [Full Text] [Related]
19. [Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
Ohta H; Ushiki T; Mizuno K; Togashi T; Watanabe K; Seki K; Ishikawa T; Yoshida T; Kamimura T; Baba Y; Mafune Y; Ishikawa N
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1267-71. PubMed ID: 16969023
[TBL] [Abstract] [Full Text] [Related]
20. [Usefulness of gemcitabine in the treatment of advanced pancreatic cancer in terms of its clinical benefits].
Shiozawa S; Tsuchiya A; Kumazawa K; Ogawa K
Gan To Kagaku Ryoho; 2003 Apr; 30(4):483-7. PubMed ID: 12722678
[TBL] [Abstract] [Full Text] [Related]
[Next]
